MONTREAL, QUEBEC–(Marketwired – Aug 16, 2016) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has committed to invest $1 million in the Genesys Ventures III LP (“Genesys Fund”), a Canadian-based life sciences venture capital fund managed by Genesys Capital Management, Inc.
The investment in Genesys Fund is the eighth life sciences equity fund investment Knight has made to date, having committed over $125 million of the $130 million earmarked for this innovative strategy.
“We are pleased to support Genesys in their efforts to create innovative life sciences companies that will touch the lives of patients,” said Jonathan Ross Goodman, President and CEO of Knight.
About Genesys Capital Management Inc.
Genesys is one of the largest Canadian-based venture capital firms exclusively focused on the life sciences industry. Genesys Capital is focused on building companies in the high-growth sectors of healthcare and biotechnology. Through its expertise and network, Genesys accelerates the development of commercially viable emerging companies that represent promising life sciences investment opportunities.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.gud-knight.com or www.sedar.com.
This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2015. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.